Balaxi Pharmaceuticals Limited

BALAXI

INE618N01022

Pharmaceuticals

Market Closed - NSE India S.E. Other stock markets 05:28:32 07/06/2024 pm IST			5-day change	1st Jan Change
113.6 ^INR	+6.71%		-4.50%	+31.43%

29/05	Balaxi Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	CI
09/05	Balaxi Pharmaceuticals Limited Appoints Mahesh Inani as the Compliance Officer	CI

Balaxi Pharmaceuticals Limited Announces Resignation of Rakesh Khanna as an Additional Director (Independent Category)

March 02, 2021 at 05:44 pm IST

Balaxi Pharmaceuticals Limited announced that Mr. Rakesh Khanna has resigned as an Additional Director (Independent category) with effect from 1 March, 2021. Reason for resignation: Due to personal reasons. Further, the Company has received confirmation from Mr. Rakesh Khanna that there are no other material reasons for his resignation other than that specified.

Latest news about Balaxi Pharmaceuticals Limited

Balaxi Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	29/05	CI
Balaxi Pharmaceuticals Limited Appoints Mahesh Inani as the Compliance Officer	09/05	CI
Balaxi Pharmaceuticals Limited Announces Resignation of Purnima Singh Kamble as Independent Director	08/05	CI
Balaxi Pharmaceuticals Limited Announces Resignation of Udayan Shukla as Company Secretary and Compliance Officer	04/05	CI
Balaxi Pharmaceuticals Limited Incorporates New Wholly Owned Subsidiary in Chile	14/02	CI
Balaxi Pharmaceuticals Limited Announces Update on Company's Pharmaceutical Formulation Plant	09/02	CI
Balaxi Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	09/02	CI
Balaxi Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	02/11	CI
Balaxi Pharmaceuticals Limited completed the acquisition of Balaxi Healthcare Ecuador S.A.S.	01/23/01	CI
Balaxi Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	03/23/03	CI
Balaxi Pharmaceuticals Limited agreed to acquire Balaxi Healthcare Ecuador S.A.S. for $0.04 million.	03/23/03	CI
Balaxi Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023	29/23/29	CI
Balaxi Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	01/23/01	CI
Balaxi Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	05/22/05	CI
Balaxi Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2022	02/22/02	CI
Balaxi Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2022	23/22/23	CI
Balaxi Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	09/22/09	CI
Balaxi Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2021	28/21/28	CI
Balaxi Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2021	17/21/17	CI
Balaxi Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2021	20/21/20	CI
Balaxi Pharmaceuticals Limited Announces Resignation of Rakesh Khanna as an Additional Director (Independent Category)	02/21/02	CI
Balaxi Pharmaceuticals Limited Reports Earnings Results for the Third Quarter Ended December 31, 2020	19/21/19	CI
Balaxi Ventures Limited will Change its Name to Balaxi Pharmaceuticals Limited	20/20/20	CI
Balaxi Pharmaceuticals Limited Appoints Chinta Shalini as Company Secretary and Compliance Officer	13/20/13	CI
Balaxi Ventures to Expand into Three Central American Markets	30/20/30	CI

Chart Balaxi Pharmaceuticals Limited

Duration

Period

More charts

Company Profile

Balaxi Pharmaceuticals Limited is an India-based company. The Company operates as an intellectual property right (IPR)-based pharmaceutical company. The Company primarily operates in frontier markets across Latin America and Africa. The Company is focusing on frontier markets, with a growing portfolio of drugs across multiple therapeutic segments. It has a portfolio across multiple therapeutic segments, stock & sell models, and supplies branded and generic medicines. The Companyâs products include Anti-biotic, Analgesic, Medical Device, Vitamins, Anti-Malaria, Erectile Dysfunction, Hypertension, Anti-Asthma, Steroid, Anti-Helminthic, Anti-Ulcer, Hygiene, Anticholinergic, Dietary Supplement, Diuretic, Hormone, Anti-Emetic, Bronchodilator, Local Anesthetic, Anemia, Anti-Diarrhea, Antihistamine, Hypotension, Antacid, Anti-Tuberculosis, Insect Repellents and Laxative. Its subsidiary is Balaxi Global DMCC, Dubai.

Sector

Pharmaceuticals

Calendar

31/07/2024 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Pharmaceuticals Wholesale

	1st Jan change	Capi.
BALAXI PHARMACEUTICALS LIMITED	+31.43%	69.12M
MCKESSON CORPORATION	+26.77%	76.29B
CARDINAL HEALTH, INC.	-2.27%	23.99B
SINOPHARM GROUP CO. LTD.	+10.27%	9.01B
SHANGHAI PHARMACEUTICALS HOLDING CO., LTD	+12.25%	8.67B
HUADONG MEDICINE CO., LTD	-24.34%	7.58B
H. LUNDBECK A/S	+12.70%	5.18B
GALENICA AG	+2.89%	4.16B
EBOS GROUP LIMITED	-4.96%	3.98B
JOINTOWN PHARMACEUTICAL GROUP CO., LTD	-1.36%	3.63B